EXTENDED-RELEASE FORMULATION FOR REDUCING THE FREQUENCY OF URINATION AND METHOD OF USE THEREOF
Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent formulated for extended-release.
1 . A method for reducing the frequency of urination, comprising:
administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising a first analgesic agent selected from the group consisting of aspirin, ibuprofen; naproxen sodium, indomethacin, nabumetone; and acetaminophen,
wherein said pharmaceutical composition is formulated in an extended-release formulation.
2 . The method of claim 1 , wherein said extended-release formulation comprises an enteric coating.
3 . The method of claim 1 , wherein said first analgesic agent is selected from the group consisting of aspirin, ibuprofen, naproxen sodium, indomethacin, nabumetone, and acetaminophen and is administered at a daily dose of 0.1-100 μg.
4 . The method of claim 1 , wherein said first analgesic agent is selected from the group consisting of aspirin, ibuprofen, naproxen sodium, indomethacin, nabumetone, and acetaminophen and is administered at a daily dose of 0.1-10 mg.
5 . The method of claim 1 , wherein said pharmaceutical composition is administered 1-3 hours before bedtime.
6 . The method of claim 1 , wherein said pharmaceutical composition further comprises a second analgesic agent selected from the group consisting of aspirin, ibuprofen, naproxen sodium, indomethacin, nabumetone, and acetaminophen, wherein said second analgesic agent is different from said first analgesic agent.
7 . The method of claim 1 , wherein said pharmaceutical composition further comprises a first antimuscurinic agent selected from the group consisting of oxybutynin, solifenacin, darifenacin and atropine.
8 . A method for reducing the frequency of urination, comprising:
administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising:
a first component formulated for immediate-release; and
a second component formulated for extended-release,
wherein said first component and said second component each comprises an analgesic agent selected from the group consisting of aspirin, ibuprofen, naproxen sodium, indomethacin, nabumetone, and acetaminophen.
9 . The method of claim 8 , wherein said second component is coated with an enteric coating.
10 . The method of claim 8 , wherein said first component further comprises an antimuscurinic agent selected from the group consisting of oxybutynin, solifenacin, darifenacin and atropine.
11 . The method of claim 8 , wherein said second component further comprises an antimuscurinic agent selected from the group consisting of oxybutynin, solifenacin, darifenacin and atropine.
12 . The method of claim 8 , wherein each of said first and second components further comprises an antimuscurinic agent selected from the group consisting of oxybutynin, solifenacin, darifenacin and atropine.
13 . The method of claim 8 , wherein each of said first and second components comprises two analgesic agents selected from the group consisting of aspirin, ibuprofen, naproxen sodium, indomethacin, nabumetone, and acetaminophen.
14 . The method of claim 13 , wherein said two analgesic agents in said first component have a combined dose of 0.1-100 μg and wherein said two analgesic agents in said second component have a combined dose of 0.1-100 μg.
15 . The method of claim 8 , wherein said analgesic agent in said first component has a dose of 0.1-100 μg and wherein said analgesic agent in said second component has a dose of 0.1-100 μg.
16 . A method for reducing the frequency of urination, comprising:
administering to a person in need thereof a first pharmaceutical composition comprising a diuretic; and
administering to said person a second pharmaceutical composition comprising one or more analgesic agents,
wherein said first pharmaceutical composition is dosed and formulated to have a diuretic effect within 6 hours of administration and is administered at least 8 hours prior to bedtime, and wherein said second pharmaceutical composition is formulated for extended-release and administered within 2 hours prior to bedtime.
17 . The method of claim 16 , wherein said second pharmaceutical composition further comprises one or more antimuscurinic agents.
18 . A pharmaceutical composition, comprising:
two or more analgesic agents selected from the group consisting of aspirin, ibuprofen, naproxen sodium, indomethacin, nabumetone, and acetaminophen; and
a pharmaceutically acceptable carrier,
wherein said two or more analgesic agents are formulated for extended-release.
19 . A method for treating nocturia, comprising:
administering to a person in need thereof a pharmaceutical composition comprising one or more analgesic agents and one or more antidiuretic agent, wherein said pharmaceutical composition is formulated for extended-release.
20 . A pharmaceutical composition, comprising:
a first component formulated for immediate-release, wherein said first component comprises one or more analgesic agents selected from the group consisting of aspirin, ibuprofen, naproxen sodium, indomethacin, nabumetone, and acetaminophen;
a second component formulated for extended-release, wherein said second component comprises one or more analgesic agents selected from the group consisting of aspirin, ibuprofen, naproxen sodium, indomethacin, nabumetone, and acetaminophen; and
a pharmaceutically acceptable carrier.
21 . The pharmaceutical composition of claim 20 , wherein said first component, said second component or both components further comprises one or more antimuscurinic agents.
22 . The pharmaceutical composition of claim 21 , wherein said antimuscurinic agent is selected from the group consisting of oxybutynin, solifenacin, darifenacin and atropine.